Brainstorm Cell Therapeutics (BCLI) Tops Q3 EPS by 2c

November 15, 2016 9:19 AM EST
Get Alerts BCLI Hot Sheet
Trade BCLI Now!
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

Brainstorm Cell Therapeutics (NASDAQ: BCLI) reported Q3 EPS of ($0.09), $0.02 better than the analyst estimate of ($0.11).

As of September 30, 2016, the Company had cash, cash equivalents, and short-term deposits of approximately $11.2 million.

For earnings history and earnings-related data on Brainstorm Cell Therapeutics (BCLI) click here.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Earnings

Related Entities

Earnings

Add Your Comment